Diabetes Virus Detection Project, Intervention With GAD-alum
Launched by OSLO UNIVERSITY HOSPITAL · May 21, 2010
Trial Information
Current as of June 18, 2025
Terminated
Keywords
ClinConnect Summary
The aetiology of type 1 diabetes is unknown. Both genetic and environmental factors seem to be important for the destruction of insulin producing beta cells in the pancreas. Increasing indirect evidences exist that picornaviruses may either directly or indirectly through autoimmune processes destroy beta cells. New sensitive assays have been developed to detect these viruses and to study the immunological processes, especially T-cell function. Microsurgical technology has been refined, now making pancreatic biopsies a safe procedure. This study focuses on advanced in depth studies of immuno...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Newly diagnosed classical type-1 diabetes
- • Positive GAD antibodies
- • Fasting C-peptide \>0.1 mmol/l
- • Insulin dosage \>0.1 U/kg Bodyweight/day
- Exclusion Criteria:
- • Pregnancy
- • Weaning
- • Other chronic diseases than diabetes
- • Any regular medication except oral contraceptives
- • Psychiatric disturbances
About Oslo University Hospital
Oslo University Hospital is a leading academic medical center in Norway, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital integrates cutting-edge scientific inquiry with patient care, fostering an environment that promotes the development of new therapies and treatment strategies. With a multidisciplinary approach, Oslo University Hospital collaborates with various stakeholders, including researchers, healthcare professionals, and industry partners, to enhance clinical outcomes and contribute to the global medical community. Its dedication to ethical standards and patient safety ensures that all trials are conducted with the highest level of integrity and respect for participant welfare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oslo, , Norway
Patients applied
Trial Officials
Knut Dahl-Jorgensen, Prof
Principal Investigator
Oslo University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials